

Christian Klein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1242106/publications.pdf>

Version: 2024-02-01

282
papers

16,809
citations

28274

55
h-index

16650

123
g-index

304
all docs

304
docs citations

304
times ranked

21698
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and <i>ex vivo</i> photodynamic therapy. <i>Rheumatology</i> , 2022, 61, 2999-3009.	1.9	37
2	Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?. <i>Rheumatology</i> , 2022, 61, 2894-2904.	1.9	9
3	A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis. <i>AAPS Journal</i> , 2022, 24, 7.	4.4	2
4	Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies. <i>Biological Chemistry</i> , 2022, 403, 495-508.	2.5	6
5	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. , 2022, 10, e003766.		15
6	Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers. <i>Theranostics</i> , 2022, 12, 1373-1387.	10.0	12
7	Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. <i>Oncolmmunology</i> , 2022, 11, 2039432.	4.6	14
8	Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. <i>Oncolmmunology</i> , 2022, 11, .	4.6	15
9	The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. <i>Arthritis and Rheumatology</i> , 2021, 73, 826-836.	5.6	23
10	Anti-CD20 treatment for B-cell malignancies: current status and future directions. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 161-181.	3.1	24
11	Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN γ /CXCL10-dependent peripheral T cell recruitment in humanized murine model. <i>PLoS ONE</i> , 2021, 16, e0241091.	2.5	22
12	A modular and controllable T cell therapy platform for acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2243-2257.	7.2	24
13	Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. <i>MAbs</i> , 2021, 13, 1967714.	5.2	34
14	Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. <i>Oncolmmunology</i> , 2021, 10, 1869389.	4.6	14
15	Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. <i>Nature Communications</i> , 2021, 12, 1237.	12.8	29
16	A human receptor occupancy assay to measure anti-CD γ binding in patients with prior anti-CD γ . <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 832-843.	1.5	10
17	DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. <i>Molecular Cell</i> , 2021, 81, 1469-1483.e8.	9.7	52
18	Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. <i>Lung Cancer</i> , 2021, 155, 10-19.	2.0	28

#	ARTICLE	IF	CITATIONS
19	Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3084.	3.7	6
20	Abstract 3165: Stroma-immune landscape in lymphoma: new mechanisms of immunosuppression and therapeutic targeting. , 2021, , .		0
21	Abstract 71: The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity. , 2021, , .		0
22	Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. , 2021, 9, e002582.		14
23	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. <i>Blood</i> , 2021, 138, 2655-2669.	1.4	43
24	Single-nucleotide Fc γ 3 receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 2935-2944.	5.2	10
25	Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , 2021, 5, 2945-2957.	5.2	7
26	Abstract 1690: JAK2 downmodulation leads to interferon gamma deficient response and resistance to immunotherapy in breast cancer. , 2021, , .		1
27	Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells. <i>Journal of Immunology</i> , 2021, 207, 493-504.	0.8	8
28	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , 2021, 10, .	6.0	33
29	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. <i>MAbs</i> , 2021, 13, 1913791.	5.2	53
30	Fibroblast Activation Protein Targeted Photodynamic Therapy Selectively Kills Activated Skin Fibroblasts from Systemic Sclerosis Patients and Prevents Tissue Contraction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12681.	4.1	9
31	Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist. <i>Blood</i> , 2021, 138, 1178-1178.	1.4	1
32	Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid. <i>Pharmaceutics</i> , 2021, 13, 2105.	4.5	4
33	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 541-551.	7.1	66
34	Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. <i>Frontiers in Oncology</i> , 2020, 10, 575737.	2.8	28
35	Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis. <i>Rheumatology</i> , 2020, 59, 3952-3960.	1.9	22
36	CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins. <i>MAbs</i> , 2020, 12, 1840709.	5.2	1

#	ARTICLE	IF	CITATIONS
37	L4â€¦Synthetic agonistic receptor-activating BiTEs â€“ a modular platform for the efficient targeting of acute myeloid leukemia. , 2020, , .		0
38	P06.01â€¦Bispecific antibody-driven synthetic agonistic receptor â€“ transduced T cells mediate specific and conditional therapy in melanoma cancer models. , 2020, , .		0
39	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , the, 2020, 7, e649-e659.	4.6	24
40	L2â€¦In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific CD20-TCB antibody. , 2020, 8, A1.2-A1.		0
41	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2371-2381.	4.1	3
42	Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 628005.	2.8	3
43	Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo. <i>MAbs</i> , 2020, 12, 1834818.	5.2	7
44	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. <i>Cancers</i> , 2020, 12, 3238.	3.7	13
45	The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. <i>Cancer Research</i> , 2020, 80, 2903-2913.	0.9	30
46	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	229
47	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. , 2020, 8, e000238.		35
48	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. <i>Nature Communications</i> , 2020, 11, 3196.	12.8	43
49	CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to \hat{I}^3c cytokine stimulation via PI3K/mTOR axis. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 501-512.	4.2	8
50	141â€¦PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants. , 2020, , .		2
51	Abstract 2270: RC7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells. <i>Cancer Research</i> , 2020, 80, 2270-2270.	0.9	11
52	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 41-42.	1.4	2
53	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. <i>Oncotarget</i> , 2020, 11, 3035-3047.	1.8	4
54	Abstract 4229: Anti-P329G-CAR-T cells as a novel universal CAR-T cell platform. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 6135: Tumor-bearing non-human primates: An unrivaled model for translational cancer immunology research. , 2020, , .		3
56	Abstract LB-389: Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents. , 2020, , .		5
57	Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 29-30.	1.4	1
58	653â€¦Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release. , 2020, , .		3
59	RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies. Blood, 2020, 136, 40-40.	1.4	7
60	Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL). Blood, 2020, 136, 23-24.	1.4	1
61	Abstract PO-26: Prognostic significance of Fc gamma receptor IIB expression in the response of previously untreated diffuse large B-cell lymphomas to anti-CD20 monoclonal antibodies: Differing impact of rituximab and obinutuzumab. , 2020, , .		0
62	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. Clinical Cancer Research, 2019, 25, 5890-5900.	7.0	31
63	PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species. Journal of Pharmaceutical Sciences, 2019, 108, 3729-3736.	3.3	3
64	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunology Research, 2019, 7, 2036-2051.	3.4	39
65	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. Frontiers in Immunology, 2019, 10, 1943.	4.8	22
66	P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. Protein Engineering, Design and Selection, 2019, 32, 207-218.	2.1	6
67	DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity. MAbs, 2019, 11, 1402-1414.	5.2	8
68	Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab. Scientific Reports, 2019, 9, 13675.	3.3	9
69	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Science Translational Medicine, 2019, 11, .	12.4	178
70	A novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors. European Journal of Cancer, 2019, 110, S25.	2.8	0
71	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clinical Cancer Research, 2019, 25, 4634-4643.	7.0	49
72	Characterization of bispecific antibodies that drive synthetic agonistic receptor - transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models. European Journal of Cancer, 2019, 110, S3.	2.8	0

#	ARTICLE	IF	CITATIONS
73	Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. <i>MAbs</i> , 2019, 11, 621-631.	5.2	38
74	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019, 133, 1964-1976.	1.4	104
75	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	1.4	63
76	Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model. <i>Circulation</i> , 2019, 139, 2049-2063.	1.6	57
77	P131â€¦Targeting activated synovial fibroblasts using photodynamic therapy in human rheumatoid arthritis synovial tissue. , 2019, , .		0
78	SAT0052â€¦PHOTODYNAMIC THERAPY TARGETING ACTIVATED FIBROBLASTS INDUCES SYNOVIAL CELL DEATH IN EXPERIMENTAL ARTHRITIS. , 2019, , .		0
79	Boosting β 1 T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. <i>OncImmunity</i> , 2019, 8, 1554175.	4.6	53
80	Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , 2019, 154, 21-31.	3.8	89
81	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. <i>British Journal of Cancer</i> , 2019, 120, 79-87.	6.4	36
82	Abstract 1552: A novel PD1-IL2v immunocytokine for preferential <i>in cis</i> -activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism. <i>Cancer Research</i> , 2019, 79, 1552-1552.	0.9	4
83	Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 3963-3963.	1.4	3
84	A dual-labeled anti-FAP antibody for imaging and targeted photodynamic therapy of cancer associated fibroblasts in a pancreatic cancer mouse model. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, .	0.7	0
85	PF207 TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1â€¦CB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDEâ€¦MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN. <i>HemaSphere</i> , 2019, 3, 56.	2.7	0
86	Abstract 1129: Monitoring intratumoral CD8 T cell infiltrates in human stem cell engrafted mice during single agent and combination immunotherapy with T cell bispecific antibodies using the human PET-tracer ⁸⁹ Zr-Df-IAB22M2C. , 2019, , .		0
87	Abstract 1537: Polatuzumab Vedotin alone or in-combination with anti-CD20 antibody significantly enhanced overall survival in xenografted NSG mice against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL). , 2019, , .		1
88	Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide. <i>Blood</i> , 2019, 134, 4450-4450.	1.4	4
89	Abstract 1129: Monitoring intratumoral CD8 T cell infiltrates in human stem cell engrafted mice during single agent and combination immunotherapy with T cell bispecific antibodies using the human PET-tracer ⁸⁹ Zr-Df-IAB22M2C. , 2019, , .		0
90	Abstract 1537: Polatuzumab Vedotin alone or in-combination with anti-CD20 antibody significantly enhanced overall survival in xenografted NSG mice against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL). , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	Abstract 1552: A novel PD1-IL2v immunocytokine for preferential cis-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism. , 2019, , .		0
92	The PI3KÎ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. Journal of Immunology, 2018, 200, 2304-2312.	0.8	15
93	New insights in Type I and <sc>II CD</sc>20 antibody mechanismsâ€ofâ€action with a panel of novel <sc>CD</sc>20 antibodies. British Journal of Haematology, 2018, 180, 808-820.	2.5	51
94	Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy. Clinical Cancer Research, 2018, 24, 3325-3333.	7.0	51
95	Arming T cells with activating FcÎ³R11a receptors for antibody redirected lysis of cancer cells. European Journal of Cancer, 2018, 92, S21.	2.8	0
96	Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. Rheumatology, 2018, 57, 737-747.	1.9	22
97	CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clinical Cancer Research, 2018, 24, 4785-4797.	7.0	146
98	P107â€...Targeting activated synovial fibroblasts using photodynamic therapy in experimental arthritis. , 2018, , .		0
99	Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. Leukemia and Lymphoma, 2018, 59, 1482-1485.	1.3	8
100	GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. Haematologica, 2018, 103, e78-e81.	3.5	13
101	Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study. Oncotarget, 2018, 9, 7162-7174.	1.8	13
102	A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. Journal of Autoimmunity, 2018, 95, 1-14.	6.5	129
103	p95HER2â€T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	12.4	59
104	Variable heavyâ€variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly. Protein Engineering, Design and Selection, 2018, 31, 289-299.	2.1	22
105	Proof of concept and mode of action of a novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors. European Journal of Cancer, 2018, 92, S19.	2.8	0
106	Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. BioMed Research International, 2018, 2018, 1-9.	1.9	20
107	Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor â€ Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models. European Journal of Cancer, 2018, 92, S20.	2.8	0
108	A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nature Medicine, 2018, 24, 994-1004.	30.7	783

#	ARTICLE	IF	CITATIONS
109	Abstract 1788: Enhanced in vitro/in vivo cytotoxicity against Burkitt lymphoma/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu- anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab. , 2018, , .		2
110	Abstract 2774: The triple combination of the FAP-IL2v immunocytokine with PD-L1 checkpoint inhibitory and CD40 agonistic antibodies results in long-term tumor control in the orthotopic PancO2 model. , 2018, , .		1
111	Abstract 5621: FAP-4-1BBL: A novel versatile tumor-stroma targeted 4-1BB agonist for combination immunotherapy with checkpoint inhibitors, T-cell bispecific antibodies, and ADCC-mediating antibodies. , 2018, , .		1
112	Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment. , 2018, , .		0
113	Abstract 2565: EBV peptide-derived vaccine significantly enhanced in vitro cytotoxicity against EBV-positive B-cell lymphoma (EBV-BL) treatment using TMV-based delivery system. , 2018, , .		0
114	Abstract 957: Design of CD19-4-1BBL, a novel CD19-targeted 4-1BB ligand for combination therapy with CD20 T-cell bispecific antibodies and CD20 antibodies. , 2018, , .		0
115	Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma. Blood, 2018, 132, 5381-5381.	1.4	0
116	Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. OncoImmunology, 2017, 6, e1277306.	4.6	190
117	A human immunodeficiency syndrome caused by mutations in CARMIL2. Nature Communications, 2017, 8, 14209.	12.8	103
118	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Advances in Therapy, 2017, 34, 324-356.	2.9	128
119	Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell, 2017, 31, 396-410.	16.8	251
120	Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology, 2017, 56, 1227-1237.	1.9	124
121	A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia, 2017, 31, 1611-1621.	7.2	37
122	Targeting key angiogenic pathways with a bispecific Cross<sc>MA</sc> optimized for neovascular eyeAdiseases. EMBO Molecular Medicine, 2017, 9, 985-985.	6.9	7
123	Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. Blood, 2017, 129, 2636-2644.	1.4	86
124	Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert Opinion on Investigational Drugs, 2017, 26, 1145-1162.	4.1	6
125	Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). Annals of Oncology, 2017, 28, iii151.	1.2	18
126	PD-1 IMMUNE CHECKPOINT BLOCKADE IMPROVES ANTI-CD20 BASED IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA. Hematological Oncology, 2017, 35, 257-258.	1.7	0

#	ARTICLE	IF	CITATIONS
127	Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior <i>in vivo</i> efficacy compared to ONO/GS-4059 in combination with rituximab. <i>Leukemia and Lymphoma</i> , 2017, 58, 699-707.	1.3	15
128	A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 129-140.	4.2	112
129	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody. <i>Journal of Nuclear Medicine</i> , 2017, 58, 151-155.	5.0	32
130	OUP accepted manuscript. <i>Protein Engineering, Design and Selection</i> , 2017, 30, 649-656.	2.1	13
131	Abstract 3629: Engineering a novel asymmetric head-to-tail 2+1 T-cell bispecific (2+1 TCB) IgG antibody platform with superior T-cell killing compared to 1+1 asymmetric TCBs. , 2017, , .		3
132	Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells. , 2017, , .		3
133	Abstract 3658: Dendritic cells dictate the responsiveness of PD-L1 blockade in cancer. , 2017, , .		2
134	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. <i>Oncotarget</i> , 2017, 8, 113895-113909.	1.8	15
135	Abstract 1594: Enhancement of the anti-tumor activity of CEA TCB via combination with checkpoint blockade by PD-L1 and interleukin-2 variant immunocytokine. , 2017, , .		0
136	A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2130-2142.	4.1	15
137	Targeting key angiogenic pathways with a bispecific Cross α MA β optimized for neovascular eye diseases. <i>EMBO Molecular Medicine</i> , 2016, 8, 1265-1288.	6.9	185
138	Solution structure and binding specificity of the p63 DNA binding domain. <i>Scientific Reports</i> , 2016, 6, 26707.	3.3	18
139	Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. <i>Journal of Immunotherapy</i> , 2016, 39, 279-289.	2.4	28
140	<i>In Vivo</i> Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing. <i>Clinical Cancer Research</i> , 2016, 22, 4417-4427.	7.0	58
141	Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). <i>European Journal of Haematology</i> , 2016, 97, 461-470.	2.2	23
142	Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. <i>Protein Engineering, Design and Selection</i> , 2016, 29, 457-466.	2.1	226
143	TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. <i>Protein Engineering, Design and Selection</i> , 2016, 29, 467-475.	2.1	22
144	A TLR7 agonist enhances the anti-tumour efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in a murine lymphoma model. <i>European Journal of Cancer</i> , 2016, 61, S211.	2.8	0

#	ARTICLE	IF	CITATIONS
145	CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. <i>Oncolmmunology</i> , 2016, 5, e1203498.	4.6	94
146	OP0159â€¦Improving B-Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Resistance To Rituximab and The Potential of Obinutuzumab. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 116.1-116.	0.9	2
147	RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 946-957.	4.1	99
148	The use of CrossMAb technology for the generation of bi- and multispecific antibodies. <i>MAbs</i> , 2016, 8, 1010-1020.	5.2	132
149	Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin α _v β ₃ . <i>Journal of Nuclear Medicine</i> , 2016, 57, 467-472.	5.0	38
150	XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. <i>MAbs</i> , 2016, 8, 811-827.	5.2	28
151	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , 2016, 14, 1748-1760.	6.4	90
152	Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. <i>MAbs</i> , 2016, 8, 562-573.	5.2	19
153	A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3286-3297.	7.0	260
154	Activation of cytomegalovirus-specific CD8 ⁺ T-cell response by antibody-mediated peptide-major histocompatibility class I complexes. <i>Oncolmmunology</i> , 2016, 5, e1052930.	4.6	0
155	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. <i>Oncolmmunology</i> , 2016, 5, e1062969.	4.6	27
156	Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry. <i>MAbs</i> , 2016, 8, 49-55.	5.2	29
157	CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies. <i>Blood</i> , 2016, 128, 1836-1836.	1.4	22
158	The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models. <i>Blood</i> , 2016, 128, 4178-4178.	1.4	2
159	Abstract 2955: Herceptarg, a novel heterodimeric biparatopic common light chain IgG1 antibody based on trastuzumab and pertuzumab, exerts potent anti-tumoral activity. , 2016, , .		0
160	Abstract 1494: Combination of CEA TCB, a novel T-cell bispecific antibody for the treatment of solid tumors, with PD-L1 checkpoint blockade. , 2016, , .		0
161	Abstract 2217: Combining CEA-IL2v and FAP-IL2v immunocytokines with PD-L1 checkpoint blockade. <i>Cancer Research</i> , 2016, 76, 2217-2217.	0.9	3
162	Abstract 3893: Obinutuzumab (GA101) versus rituximab against rituximab-sensitive and -resistant Burkitt lymphoma (BL) differentially phosphorylate BCR, Fc-gamma receptor, and natural killer cell-mediated cytotoxicity signaling pathways. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
163	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 171, 763-775.	2.5	83
164	Efficacy of phosphatidylinositol 3-kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. <i>International Journal of Cancer</i> , 2015, 137, 2234-2242.	5.1	39
165	Activatory and Inhibitory Fcγ3 Receptors Augment Rituximab-mediated Internalization of CD20 Independent of Signaling via the Cytoplasmic Domain. <i>Journal of Biological Chemistry</i> , 2015, 290, 5424-5437.	3.4	44
166	Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers. <i>Blood Cancer Journal</i> , 2015, 5, e367-e367.	6.2	12
167	Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>Journal of Autoimmunity</i> , 2015, 56, 66-80.	6.5	87
168	Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. <i>Journal of Nuclear Medicine</i> , 2015, 56, 778-783.	5.0	84
169	ITOC2 037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumor activity against solid tumours. <i>European Journal of Cancer</i> , 2015, 51, S13.	2.8	1
170	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. <i>Cancer Immunology Research</i> , 2015, 3, 1344-1355.	3.4	285
171	Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules. <i>Cancer Immunology Research</i> , 2015, 3, 764-776.	3.4	19
172	Obinutuzumab in hematologic malignancies: Lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015, 41, 784-792.	7.7	52
173	How to outsmart NK cell tolerance. <i>Oncotarget</i> , 2015, 4, e1016708.	4.6	8
174	Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. <i>Oncology Research and Treatment</i> , 2015, 38, 185-192.	1.2	49
175	Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 364.	6.3	34
176	Abstract 2460: Dissecting the in vitro and in vivo mechanism of action of obinutuzumab (GA101) in preclinical models using an immune effector-dead version of obinutuzumab. , 2015, , .		1
177	A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys. <i>Blood</i> , 2015, 126, 2998-2998.	1.4	4
178	CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo. <i>Blood</i> , 2015, 126, 4157-4157.	1.4	2
179	Abstract 2481: CEA TCB, a novel T-cell bispecific antibody with potent in vitro and in vivo antitumor activity against solid tumors. , 2015, , .		1
180	Abstract 2479: Obinutuzumab compared to Rituximab significantly enhances cell death, antibody dependent cytotoxicity (ADCC) and improves overall survival against CD20+rituximab-sensitive/-resistant Burkitt Lymphoma (BL) and precursor Lymphoblastic L. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
181	Abstract IA07: Enhancing immune effector function via antibody engineering. , 2015, , .		0
182	Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins. Blood, 2015, 126, 1550-1550.	1.4	0
183	Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leukemia and Lymphoma, 2014, 55, 2151-5160.	1.3	44
184	Development of Bispecific Molecules for the In Situ Detection of Protein-Protein Interactions and Protein Phosphorylation. Chemistry and Biology, 2014, 21, 357-368.	6.0	7
185	Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity. Journal of Immunology, 2014, 192, 2252-2260.	0.8	127
186	A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties. Journal of Biological Chemistry, 2014, 289, 18693-18706.	3.4	48
187	KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity. Journal of Immunology, 2014, 192, 5618-5624.	0.8	68
188	870: A new bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. European Journal of Cancer, 2014, 50, S213.	2.8	0
189	S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer. , 2014, 2, .		7
190	Abstract 2027: Novel 3D tumor-immune cell spheroid models for assessment of cancer immunotherapy agents. , 2014, , .		2
191	Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodies in vitro and in vivo. , 2014, , .		2
192	Abstract 650: KIR/HLA interactions negatively affect rituximab, but not GA101 (obinutuzumab)-induced ADCC. , 2014, , .		2
193	Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo. Blood, 2014, 124, 1765-1765.	1.4	14
194	Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?. Blood, 2014, 124, 1980-1980.	1.4	2
195	The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab. Blood, 2014, 124, 3342-3342.	1.4	5
196	Abstract 3631: Modulation of monocyte- and macrophage-mediated antibody-dependent cell phagocytosis and cytotoxicity (ADCP/ADCC) by Fc engineering of therapeutic antibodies. , 2014, , .		0
197	Abstract 2592: Tumor targeting and pharmacodynamics of the novel targeted immunocytokine FAP-IL2v in a tumor-bearing Rhesus monkey. , 2014, , .		1
198	ADCC Induced By Monoclonal Anti-CD20 Antibodies in a 3D Follicular Lymphoma model : Signaling and Spatial Localization. Blood, 2014, 124, 3114-3114.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity. <i>Blood</i> , 2014, 124, 1780-1780.	1.4	1
200	Recombinant Human IL-15 <i>Trans</i> -Presentation by B Leukemic Cells from Chronic Lymphocytic Leukemia Induces Autologous NK Cell Proliferation Leading to Improved Anti-CD20 Immunotherapy. <i>Journal of Immunology</i> , 2013, 191, 3634-3640.	0.8	28
201	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. <i>Leukemia and Lymphoma</i> , 2013, 54, 2500-2505.	1.3	58
202	Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 440-446.	0.8	24
203	Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. <i>PLoS ONE</i> , 2013, 8, e61953.	2.5	30
204	Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. <i>MAbs</i> , 2013, 5, 22-33.	5.2	280
205	Deconstruction of a Nutlin: Dissecting the Binding Determinants of a Potent Protein-Protein Interaction Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 660-665.	2.8	51
206	Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2031-2042.	4.1	301
207	Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy. <i>Clinical Cancer Research</i> , 2013, 19, 6730-6740.	7.0	179
208	Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death. <i>EMBO Molecular Medicine</i> , 2013, 5, 1821-1834.	6.9	39
209	Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. <i>Blood Cancer Journal</i> , 2013, 3, e131-e131.	6.2	46
210	A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. <i>Oncogene</i> , 2013, 32, 5593-5601.	5.9	53
211	Response to: Monoclonal antibodies targeting CD20. <i>MAbs</i> , 2013, 5, 337-338.	5.2	12
212	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , 2013, 122, 3482-3491.	1.4	206
213	Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.. , 2013, , .		2
214	Abstract PR8: Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer.. , 2013, , .		2
215	Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer. <i>Blood</i> , 2013, 122, 2278-2278.	1.4	9
216	Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies. <i>Blood</i> , 2013, 122, 4412-4412.	1.4	6

#	ARTICLE	IF	CITATIONS
217	A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors. PLoS ONE, 2013, 8, e54923.	2.5	61
218	Abstract B69: Novel MHC class I antibody fusions for cancer treatment.. , 2013, , .		0
219	Abstract B86: Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficiency. , 2013, , .		0
220	Abstract LB-264: Development of 3D microtissue models to study the activity of novel tumor-targeted immunotherapeutics.. , 2013, , .		0
221	Glycoengineering of Therapeutic Antibodies. Arzneimittelforschung, 2012, 62, S4-S5.	0.4	0
222	Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs, 2012, 4, 653-663.	5.2	168
223	Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Engineering, Design and Selection, 2012, 25, 551-560.	2.1	40
224	Development of tetravalent IgG1 dual targeting IGF-1R&EGFR antibodies with potent tumor inhibition. Archives of Biochemistry and Biophysics, 2012, 526, 206-218.	3.0	44
225	Bispecific Antibody Derivatives Based on Full-Length IgG Formats. Methods in Molecular Biology, 2012, 901, 247-263.	0.9	16
226	Abstract LB-236: M4-3-ML2, a novel glycoengineered humanized IgG1 antibody, targeting a membrane-proximal epitope of MCSP/CSPG4 exhibits potent ADCC induction in vitro and in vivo anti-tumoral efficacy in disseminated melanoma models. , 2012, , .		2
227	Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. Journal of Clinical Investigation, 2012, 122, 1991-2005.	8.2	376
228	Abstract 2319: Dual inhibition of Ang-2 and VEGF via a novel human bispecific bivalent IgG1 CrossMAB shows potent anti-angiogenic, antitumoral, and antimetastatic efficacy and leads to a reduced side effect profile compared to single therapies. , 2012, , .		0
229	Obinutuzumab (GA101) Displays Higher Efficiency Than Rituximab in a Follicular Lymphoma 3D Model. Blood, 2012, 120, 4868-4868.	1.4	0
230	Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11187-11192.	7.1	367
231	1242 POSTER Functional Comparison of IGF-1R Antibodies and Possible Implications for Clinical Safety and Efficacy. European Journal of Cancer, 2011, 47, S157.	2.8	0
232	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood, 2011, 117, 510-518.	1.4	57
233	Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood, 2011, 118, 358-367.	1.4	203
234	CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood, 2011, 118, 5178-5188.	1.4	44

#	ARTICLE	IF	CITATIONS
235	Comparison of the <i>in vitro</i> effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. British Journal of Haematology, 2011, 152, 295-306.	2.5	118
236	A Human Neutralizing Antibody Specific to Ang-2 Inhibits Ocular Angiogenesis. Microcirculation, 2011, 18, 598-607.	1.8	29
237	Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. Molecular Cancer Therapeutics, 2011, 10, 178-185.	4.1	125
238	Abstract 3285: Ang-2-VEGF CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 function mediates potent anti-tumoral and anti-angiogenic efficacy. , 2011, , .		1
239	Abstract LB-212: XGFR, an Fc-engineered dual signaling inhibitor targeting IGF-1R and EGFR. , 2011, , .		1
240	Antibodies against CD20 or B-Cell Receptor Induce Similar Transcription Patterns in Human Lymphoma Cell Lines. PLoS ONE, 2011, 6, e16596.	2.5	20
241	Abstract LB-397: Functional characterization of IGF-1R antibodies and possible implications for clinical safety and efficacy. , 2011, , .		0
242	Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates. Blood, 2010, 116, 3373-3374.	1.4	8
243	BclxL Changes Conformation upon Binding to Wild-type but Not Mutant p53 DNA Binding Domain. Journal of Biological Chemistry, 2010, 285, 3439-3450.	3.4	70
244	232 Unique molecular recognition of CD20 by the type II CD20 antibody GA101. European Journal of Cancer, Supplement, 2010, 8, 75-76.	2.2	0
245	489 LC06, a novel angiopoietin-2 selective human antibody with potent anti-tumoral and anti-angiogenic efficacy in different xenograft models. European Journal of Cancer, Supplement, 2010, 8, 156-157.	2.2	0
246	Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 2010, 115, 4393-4402.	1.4	782
247	Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263. Blood, 2010, 116, 3915-3915.	1.4	3
248	Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs. the Type I CD20 Antibodies Rituximab and Ofatumumab. Blood, 2010, 116, 3925-3925.	1.4	5
249	CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism. Blood, 2010, 116, 3979-3979.	1.4	0
250	Enhanced Killing of Human B Lymphoma Targets by Combined Use of Cytokine Induced Killer (CIK) Cultures and Anti-CD20 Antibodies. Blood, 2010, 116, 4285-4285.	1.4	0
251	Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells. Blood, 2010, 116, 2459-2459.	1.4	1
252	Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAVi6) Targeting VEGF and Angiopoietin-2. Blood, 2010, 116, 4304-4304.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Candidate Biomarkers of Response to an Experimental Cancer Drug Identified through a Large-scale RNA Interference Genetic Screen. <i>Clinical Cancer Research</i> , 2009, 15, 5811-5819.	7.0	9
254	Antikörper – neue Krebsmedikamente. Gezielt wirksame Biomedizin. <i>Chemie in Unserer Zeit</i> , 2009, 43, 328-338.	0.1	1
255	Short hairpin RNA-mediated silencing of fucosyltransferase 8 in Chinese hamster ovary cells for the production of antibodies with enhanced antibody immune effector function. <i>Biotechnology and Applied Biochemistry</i> , 2009, 53, 31-37.	3.1	23
256	504 POSTER GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor efficacy in Non-Hodgkin lymphoma xenograft models and superior B cell depletion. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 160.	2.2	2
257	Targeting the p53/MDM2 Pathway for Cancer Therapy. , 2008, , 19-56.		0
258	The Low Molecular Weight Proteome of <i>Halobacterium salinarum</i> . <i>Journal of Proteome Research</i> , 2007, 6, 1510-1518.	3.7	63
259	An NMR-Based Antagonist Induced Dissociation Assay for Targeting the Ligand-Protein and Protein-Protein Interactions in Competition Binding Experiments. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4382-4387.	6.4	43
260	A Novel Synthesis of Highly Substituted Perhydropyrrolizines, Perhydroindolizines, and Pyrrolidines: Inhibition of the Peptidyl-Prolylcis/trans Isomerase (PPLase) Pin1. <i>Helvetica Chimica Acta</i> , 2007, 90, 217-259.	1.6	18
261	GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.. <i>Blood</i> , 2007, 110, 2348-2348.	1.4	17
262	WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. VOLUME 281 (2006) PAGES 8600-8606. <i>Journal of Biological Chemistry</i> , 2007, 282, 6916.	3.4	0
263	214 POSTER Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 66-67.	2.2	13
264	p53 – A Natural Cancer Killer: Structural Insights and Therapeutic Concepts. <i>Angewandte Chemie - International Edition</i> , 2006, 45, 6440-6460.	13.8	98
265	WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization. <i>Journal of Biological Chemistry</i> , 2006, 281, 8600-8606.	3.4	208
266	Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.. <i>Blood</i> , 2006, 108, 229-229.	1.4	39
267	Cooperative Binding of p53 to DNA: Regulation by Protein-Protein Interactions through a Double Salt Bridge. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 5247-5251.	13.8	45
268	In vitro folding and characterization of the p53 DNA binding domain. <i>Biological Chemistry</i> , 2004, 385, 95-102.	2.5	5
269	Targeting the p53-MDM2 interaction to treat cancer. <i>British Journal of Cancer</i> , 2004, 91, 1415-1419.	6.4	177
270	In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. <i>Science</i> , 2004, 303, 844-848.	12.6	4,204

#	ARTICLE	IF	CITATIONS
271	Backbone 1H, 13C and 15N resonance assignments for the 25.8 kDa DNA binding domain of the human p63 protein. <i>Journal of Biomolecular NMR</i> , 2003, 26, 377-378.	2.8	5
272	The N-terminal Domain of p53 is Natively Unfolded. <i>Journal of Molecular Biology</i> , 2003, 332, 1131-1141.	4.2	225
273	p53 Contains Large Unstructured Regions in its Native State. <i>Journal of Molecular Biology</i> , 2002, 322, 917-927.	4.2	242
274	Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53. <i>Biochemistry</i> , 2001, 40, 336-344.	2.5	279
275	NMR Spectroscopy Reveals the Solution Dimerization Interface of p53 Core Domains Bound to Their Consensus DNA. <i>Journal of Biological Chemistry</i> , 2001, 276, 49020-49027.	3.4	75
276	High Thermostability and Lack of Cooperative DNA Binding Distinguish the p63 Core Domain from the Homologous Tumor Suppressor p53. <i>Journal of Biological Chemistry</i> , 2001, 276, 37390-37401.	3.4	63
277	Isolation and characterization of glycosylphosphatidylinositol-anchored, mucin-like surface glycoproteins from bloodstream forms of the freshwater-fish parasite <i>Trypanosoma carassii</i> . <i>Biochemical Journal</i> , 2000, 345, 693.	3.7	13
278	Proteophosphoglycans of <i>Leishmania mexicana</i> : Identification, purification, structural and ultrastructural characterization of the secreted promastigote proteophosphoglycan pPPG2, a stage-specific glycoisoform of amastigote aPPG. <i>Biochemical Journal</i> , 1999, 344, 775-786.	3.7	16
279	Proteophosphoglycans of <i>Leishmania mexicana</i> : Molecular cloning and characterization of the <i>Leishmania mexicana</i> ppg2 gene encoding the proteophosphoglycans aPPG and pPPG2 that are secreted by amastigotes and promastigotes. <i>Biochemical Journal</i> , 1999, 344, 787-795.	3.7	23
280	Proteophosphoglycans of <i>Leishmania mexicana</i> . <i>Biochemical Journal</i> , 1999, 344, 775.	3.7	12
281	Proteophosphoglycans of <i>Leishmania mexicana</i> . <i>Biochemical Journal</i> , 1999, 344, 787.	3.7	8
282	[⁶⁸ Ga]Ga-DOTA-Siglec-9 Detects Pharmacodynamic Changes of FAP-Targeted IL2 Variant Immunotherapy in B16-FAP Melanoma Mice. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1